Search

Displaying results 2461 - 2470 of 8517 in total
  1. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … A second focus was on the sequence Lys-Pro-Val (11-13) that is known to be important for antimicrobial activity.

  2. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.

  3. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    The prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals. … The approval of cenegermin consequently provides a novel topical treatment that has the potential capacity to offer total corneal healing for many patients who may use the agent.

  4. Drug

    Mosedipimod

    go.drugbank.com/drugs/DB12592
    Investigational

    Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

  5. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD. … This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination.

  6. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.

  7. Drug

    Namilumab

    go.drugbank.com/drugs/DB13037
    Investigational

    Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

  8. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  9. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    C1 esterase inhibitor has also been shown to inhibit the action of thrombin within the coagulation pathway, and tPA and plasmin within the fibrinolytic pathway. … Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.

  10. Drug

    Pancrelipase

    go.drugbank.com/drugs/DB00085
    ApprovedInvestigational

    [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.